Subgroup analyses demonstrated that Durvamulab was more cost effective for patients with NSCLC, followed by 25% or greater PD-L1 expression (willingness-to-pay threshold of $150,000 per QALY) [40]. Here, CD274 is linked to non-small cell lung carcinoma.